UCB and Biogen Idec pull plug on Phase II trial of oral MS drug
This article was originally published in Scrip
Executive Summary
UCB and Biogen Idec have discontinued a Phase II trial of their small-molecule drug CDP323 for relapsing multiple sclerosis (MS) as preliminary data show that it is not effective.